| Literature DB >> 15834405 |
Martin Hintersteiner1, Albert Enz, Peter Frey, Anne-Lise Jaton, Willy Kinzy, Rainer Kneuer, Ulf Neumann, Markus Rudin, Matthias Staufenbiel, Markus Stoeckli, Karl-Heinz Wiederhold, Hans-Ulrich Gremlich.
Abstract
As Alzheimer's disease pathogenesis is associated with the formation of insoluble aggregates of amyloid beta-peptide, approaches allowing the direct, noninvasive visualization of plaque growth in vivo would be beneficial for biomedical research. Here we describe the synthesis and characterization of the near-infrared fluorescence oxazine dye AOI987, which readily penetrates the intact blood-brain barrier and binds to amyloid plaques. Using near-infrared fluorescence imaging, we demonstrated specific interaction of AOI987 with amyloid plaques in APP23 transgenic mice in vivo, as confirmed by postmortem analysis of brain slices. Quantitative analysis revealed increasing fluorescence signal intensity with increasing plaque load of the animals, and significant binding of AOI987 was observed for APP23 transgenic mice aged 9 months and older. Thus, AOI987 is an attractive probe to noninvasively monitor disease progression in animal models of Alzheimer disease and to evaluate effects of potential Alzheimer disease drugs on the plaque load.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15834405 DOI: 10.1038/nbt1085
Source DB: PubMed Journal: Nat Biotechnol ISSN: 1087-0156 Impact factor: 54.908